Minims Cyclopentolate Hydrochloride Bausch + Lomb Ireland

Cyclopentolate Hydrochloride, the active ingredient in Minims Cyclopentolate Hydrochloride Bausch + Lomb Ireland, is an anticholinergic (cycloplegic) agent presented as eye drops for ocular use. It induces pupil dilation and temporary paralysis of the ciliary muscle to facilitate eye examinations and procedures.

GNH USA supplies Minims Cyclopentolate Hydrochloride Bausch + Lomb Ireland as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Cyclopentolate Hydrochloride is used in ophthalmic practice to produce cycloplegia and mydriasis for diagnostic and therapeutic procedures. - Eye examination: provides mydriasis to allow thorough retinal evaluation. - Refractive error assessment: induces cycloplegia to accurately measure refractive errors. - Intraocular surgery: facilitates surgical access by dilating the pupil. - Anterior segment imaging: improves visualization of anterior chamber structures.

Cyclopentolate eye drops may cause ocular and systemic adverse reactions. Common Side Effects: - Blurred vision: temporary difficulty focusing after administration. - Light sensitivity: increased discomfort in bright environments. - Stinging or burning: mild ocular irritation upon instillation. - Redness of the eye: conjunctival hyperemia. - Increased intraocular pressure: transient rise in pressure. Serious or Rare Side Effects: - Acute angle‑closure glaucoma: sudden painful vision loss requiring immediate care. - Allergic reaction: swelling, rash, or severe eye irritation. - Systemic anticholinergic effects: dry mouth, tachycardia, or confusion (rare).

When using Cyclopentolate Hydrochloride, consider the following precautions. - Contraindication: avoid in patients with known hypersensitivity to cyclopentolate or other anticholinergics. - Caution: use carefully in individuals with narrow anterior chamber angles or glaucoma risk. - Pregnancy: safety not established; prescribe only if benefit outweighs potential risk. - Breastfeeding: unknown excretion; consider risk versus benefit before use. - Interaction with other mydriatics: avoid simultaneous use to prevent excessive pupil dilation. - Store at room temperature: keep in original container, protect from light and moisture.

Cyclopentolate may interact with other medicines; monitor accordingly. Major Interactions (Avoid): - Other anticholinergic agents: additive systemic anticholinergic effects. - Monoamine oxidase inhibitors (MAOIs): potential for exaggerated ocular pressure changes. Moderate Interactions (Monitor Closely): - Topical beta‑blockers: may mask intraocular pressure rise. - Systemic antihistamines: can increase anticholinergic burden. - Sympathomimetic eye drops (e.g., phenylephrine): may cause excessive mydriasis.